Zonisamide
Ordering Recommendation
Optimize drug therapy and monitor patient adherence.
New York DOH Approval Status
Specimen Required
Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
Plain red. Also acceptable: Lavender (K2 or K3EDTA) or pink (K2 EDTA).
Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Refrigerated
Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
After separation from cells: Ambient: 1 week; Refrigerated: 1 week; Frozen: 6 weeks
Methodology
Quantitative Enzyme Multiplied Immunoassay Technique
Performed
Sun-Sat
Reported
1-4 days
Reference Interval
Effective February 19, 2013
Therapeutic Range | Not well established |
Toxic Level | Greater than 80 µg/mL |
Interpretive Data
The proposed therapeutic range for seizure control is 10-40 µg/mL. Toxic concentrations may cause coma, seizures and cardiac abnormalities. Pharmacokinetics varies widely, particularly with co-medications and/or compromised renal function.
FDA
Note
Hotline History
CPT Codes
80203
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
0097908 | Zonisamide Quantitative | 29620-2 |
Aliases
- Excegran
- Zonegran
- zonegran blood level
- zonegran concentration
- zonisamide blood concentration